January 17, 2023 01:32 PM EST
Deals
Pharma

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

Katherine Lewin

News Reporter

PwC’s phar­ma in­dus­try trends analy­sis is here — and the au­dit com­pa­ny is pre­dict­ing sev­er­al neg­a­tives amid mod­est ex­pec­ta­tions for M&A, cov­er­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times